Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

The FDA Introduces Naming Conventions for Biosimilars

Sep 02/50SN Staff/ GHLF in the news

Patient advocacy groups are praising the FDA for releasing a draft guidance that outlines the FDA’s proposed guidelines for naming biologics and biosimilars.

READ MORE

Maligned FDA Deserves Standing Ovation

Sep 02/50SN Staff/ GHLF in the news

Oftentimes, we forget how valuable our FDA is because we are used to only seeing the sensational critiques in the media: unwarranted drug approvals, inadequate surveillance, negligent public alerts or inappropriate industry influence.

READ MORE

Victory in the USA

Aug 28/50SN Staff/ Victories

Thank you Advocates! FDA Issues Draft Guidance for Biosimilar Naming: A Proposed Rule that Designates Official Names and Proper Names for Certain Biological Products Your efforts are making a difference. GHLF is pleased to share that the Food and Drug Administration (FDA) released a draft guidance requiring biological products licensed under the Public Health Service […]

READ MORE

Victory in Illinois

Aug 03/50SN Staff/ Victories

GHLF applauds our CreakyJoints community for taking action!

READ MORE

Texas Pharmaceutical & Therapeutics Committee – July Meeting outcome

Jul 29/50SN Staff/ Letters and Testimony

On July 24th, the Texas Pharmaceutical and Therapeutics (P&T) Committee, a part of the Texas Health and Human Services Commission, convened to review a number of different medications and medication classes for entry onto their Preferred Drug List (PDL) of the Texas Medicaid Formulary. A medication to alleviate symptoms of opioid-induced constipation (OIC) was one […]

READ MORE